Publications by authors named "A Yuwono Soeroto"
Objectives: We aimed to compare the clinical severity and outcome among laboratory-confirmed Omicron variant cases admitted between January and December 2022.
Methods: This is a cross-sectional study conducted in Hasan Sadikin General Hospital between January and December 2022. We enrolled patients aged ≥18 years with laboratory-confirmed Omicron infection.
Severity of COVID-19 manifestations in HIV patients: a systematic review and meta-analysis.
Eur Rev Med Pharmacol Sci
March 2024
Objective: The incidence of coronavirus disease 2019 (COVID-19) pandemic among people living with HIV (PLWH) is experiencing major increases. This demographic is vulnerable due to compromised immune function, but the individuals are subjected to antiretroviral therapy (ART), which shows potential as a treatment for the pandemic. Therefore, this study aimed to investigate the severity of various forms of COVID-19 in PLWH as opposed to the general population.
View Article and Find Full Text PDFManagement of drug-resistant tuberculosis in Indonesia: a four-year cascade of care analysis.
Lancet Reg Health Southeast Asia
March 2024
Article Synopsis
- The study in Indonesia reveals that less than one-third of drug-resistant TB (DR-TB) cases are identified and tested, with only 9.8% of true cases diagnosed.
- More than half of those diagnosed (45.1%) did not receive treatment based on proper drug susceptibility testing, and only 25.5% completed the treatment process successfully.
- There are significant delays in treatment, especially for patients referred from primary care and those with specific demographic factors, indicating a need for better access and optimization of care strategies.
Background: Pharmacokinetic data on high-dose isoniazid for the treatment of rifampicin-/multidrug-resistant tuberculosis (RR/MDR-TB) are limited. We aimed to describe the pharmacokinetics of high-dose isoniazid, estimate exposure target attainment, identify predictors of exposures, and explore exposure-response relationships in RR/MDR-TB patients.
Methods: We performed an observational pharmacokinetic study, with exploratory pharmacokinetic/pharmacodynamic analyses, in Indonesian adults aged 18-65 years treated for pulmonary RR/MDR-TB with standardized regimens containing high-dose isoniazid (10-15 mg/kg/day) for 9-11 months.
Background: Effort to search for the optimal COVID-19 treatment has continuously been attempted. Thymosin alpha-1 have immunomodulatory properties which may be beneficial in case of viral infection. This study's goal is to determine whether thymosin alpha-1 is effective in treating people with moderate-to-severe COVID-19.
View Article and Find Full Text PDF